Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Repligen Corp. (NASDAQ: RGEN).

Full DD Report for RGEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: RGEN)

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors
Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT ® STR bioreactors and Repligen’s XCell™ ATF cell retention control technology Customers to benefit from simplified, scalable solutions for intensified cell culture GÖTTINGEN, Ger...
Source: GlobeNewswire
Date: September, 04 2018 11:05
By The Numbers: Growth Leaders With Strong Momentum
Investing in high-growth stocks can generate outstanding returns when done right. In essence, a stock is simply a share in the ownership of a business, and businesses with superior growth rates tend to generate higher returns for investors over the long term. However, implementing a solid gr...
Source: SeekingAlpha
Date: August, 28 2018 10:24

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1457.1257.4657.7356.76322,707
2018-05-2142.6342.6042.8842.29234,524
2018-05-1842.1042.5842.6641.58247,922
2018-05-1742.1442.0642.2241.36138,832
2018-05-1641.9242.0742.2841.62231,216

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1424,303120,78220.1214Cover
2018-12-1321,84583,66126.1113Cover
2018-12-12112,277313,22435.8456Short
2018-12-1171,377175,08640.7668Short
2018-12-1020,28573,24027.6966Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RGEN.


About Repligen Corp. (NASDAQ: RGEN)

Logo for Repligen Corp. (NASDAQ: RGEN)

Not available

 

Contact Information

 

 

Current Management

  • Walter C. Herlihy / President, CEO

Current Share Structure

  • Market Cap: $1,860,486,816 - 05/18/2018
  • Issue and Outstanding: 43,693,913 - 05/01/2018

 


Recent Filings from (NASDAQ: RGEN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 02 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: June, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 22 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 16 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018

 

 


Daily Technical Chart for (NASDAQ: RGEN)

Daily Technical Chart for (NASDAQ: RGEN)


Stay tuned for daily updates and more on (NASDAQ: RGEN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RGEN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RGEN and does not buy, sell, or trade any shares of RGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/